Clinical trial · Observational
Mapping of Lymph Node Metastasis and Survival For pN+ Superficial Esophageal Squamous Cell Carcinoma
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
NCT05526456CI-TRIAL-00060658completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
With the deeper tumor invasion, the higher LNM rate beside the bilateral recurrent laryngeal nerves(RLN) was.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| National Cancer Center/Cancer Hospital | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Esophagectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- LNM rates of the 207 thoracic T1N+ ESCC patients.
- timeFrame
- 2012.2-2022.4
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 44 Years
- Maximum age
- 73 Years
Show eligibility criteria text
Inclusion Criteria: * Our predefined search strategy identified pT1N+ ESCC cases without preoperative treatment, between February 2012 and April 2022. Exclusion Criteria: * The patients were excluded because they were (1)less than 10 lymph nodes removed; (2) lacked specific sites of LNM; or (3) incomplete follow-up information.
References
Publications (0)
Data not yet available
No reference posted for this study.